### Enduring Learner Notification

**Society of Gynecologic Oncology - 2025 SGO Annual Meeting**

**Date of CE Release: March 18, 2025**

**Date of CE Expiration: May 18, 2025**

**Online**

**Acknowledgement of Financial Commercial Suppor**t

GSK

**Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

**Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

**Joint Accreditation Statement**

A picture containing drawing

Description automatically generatedIn support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Amedco Joint Accreditation #4008163.

Professions in scope for this activity are listed below.

**Physicians**

Amedco LLC designates this **enduring material** for a maximum of **37.75** *AMA PRA Category 1 Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses**

Amedco LLC designates this activity for a maximum of **37.75 Enduring Material** ANCC contact hours.

**Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of **37.75** **Enduring** knowledge-based CPE contact hours.

**UAN’s:**

* ACPE Topic Code 01 – Enduring: JA4008163-9999-25-085-H01-P / JA4008163-9999-25-085-H01-T (26.25 CE)
* ACPE Topic Code 04 – Enduring: JA4008163-9999-25-086-H04-P / JA4008163-9999-25-086-H04-T (5.75 CE)
* ACPE Topic Code 99 – Enduring: JA4008163-9999-25-087-H99-P / JA4008163-9999-25-087-H99-T (5.75 CE)

***NOTE to Pharmacists:*** *The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.*

**Physician Assistants**

The National Commission on Certification of Physician Assistants (NCCPA) states that *AMA PRA Category 1 Credits™* are acceptable for continuing medical education requirements for recertification for PAs.  
  
Amedco LLC designates this enduring activity for a maximum of **37.75 Enduring** **Material** *AMA PRA Category 1 Credits™*. PAs should claim only the credit commensurate with the extent of their participation in the activity.

**Nurse Practitioners**

The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. Up to **37.75 Enduring** **Material** hours**.**

**Objectives - After Attending This Program You Should Be Able To**

1. Develop and disseminate cutting edge surgical technologies and improved perioperative pathways to optimize surgical outcomes.
2. Facilitate the opportunities for scientists to bring research forward and increase patient access to novel study designs and therapies.
3. Create an environment where patients, providers, advocates and caregivers convene to discuss how to attain the outcomes that matter most to all parties.

**Disclosure of Conflict of Interest**

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-­‐6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

|  |  |  |
| --- | --- | --- |
| **First Name** | **Last Name** | **Disclosure** |
| Nadeem | Abu-Rustum | Honorarium for lecture relationship with NCCN; Honorarium for lecture relationship with Klinik Essen Mitte; Paid to Institution relationship with GRAIL |
| Mariam | AlHilli | No Relevant Financial Relationships |
| Jill | Alldredge | No Relevant Financial Relationships |
| Rebecca | Arend | Research Support relationship with Champions Oncology; Board Membership relationship with GSK; Advisory BoardLast: June 2022; Board Membership relationship with Merck; Research Support; IIT Research Support relationship with Exelixis; Research Support relationship with GOG Foundation |
| Chinmayi | Aryasomayajula | No Relevant Financial Relationships |
| Christa | Aubrey | No Relevant Financial Relationships |
| Victoria | Bae-Jump | Grant relationship with Merck; Grant relationship with Chimerix; Grant relationship with Genentech |
| Jamie | Bakkum-Gamez | Intellectual property joint filing relationship with Exact Sciences; Personal |
| Emma | Barber | Grant relationship with Eli Lilly; Consulting relationship with Merck; Consulting relationship with Merck |
| Danika | Barry | No Relevant Financial Relationships |
| Anna | Beavis | Advisory Board relationship with Ethicon; Yes; Grant relationship with Pfizer, Inc.; No |
| Stephanie | Blank | research funding to institution relationship with Merck; research funding to institution relationship with Astra Zeneca; research funding to institution relationship with Acrivon; research funding to institution relationship with Zentalis; research funding to institution relationship with Seagen/Pfizer; research funding to institution relationship with GSK |
| Allison | Brodsky | No Relevant Financial Relationships |
| Lindsay | Brubaker | Advisory Board relationship with AstraZeneca; Yes, one day advisory board involvement in October 2022 |
| Alyssa | Bujnak | No Relevant Financial Relationships |
| Stephen | Bush | Speakers' Bureau(s) relationship with Eisai; Advisory Board relationship with Astra Zenica; Consulting relationship with Glaxo Smith Kline |
| Mark | Carey | Stockholder/Shareholder - privately held relationship with Hexamer Therapeutics; Consulting relationship with Hexamer Therapeutics; Stockholder/Shareholder - publicly traded relationship with Bioatla; Stockholder/Shareholder - privately held relationship with aiGene; Stockholder/Shareholder - publicly traded relationship with Bausch Health Companies; Stockholder/Shareholder - privately held relationship with Dental Today; Speakers' Bureau(s) relationship with Verastem Oncology |
| Ilana | Cass | No Relevant Financial Relationships |
| Stephanie | Cham | No Relevant Financial Relationships |
| Laura | Chambers | No Relevant Financial Relationships |
| Junzo | Chino | Consulting relationship with Stryker; Consulting relationship with KORTUC LLC; Consulting relationship with Merck; DSMB relationship with LadeRx LLC |
| Chel Hun | Choi | No Relevant Financial Relationships |
| Hye Sook | Chon | No Relevant Financial Relationships |
| Megan | Clarke | Effective 09/24/2024 relationship with AbbVie |
| Lauren | Cobb | Consulting relationship with Verastem |
| Alexander | Cohen | No Relevant Financial Relationships |
| David | Cohn | No Relevant Financial Relationships |
| Bradley | Corr | Advisory Board relationship with Immunogen; Funded research relationship with Clovis; Ended; Advisory Board relationship with GSK; Institutional; Advisory Board relationship with Merck; Institutional; Advisory board relationship with Astrazeneca; Institutional; Funded research relationship with Immunogen; Advisory Board relationship with Gilead; Speakers' Bureau(s) relationship with Targeted Oncology; Advisory Board relationship with Easai; Speakers' Bureau(s) relationship with Top Line Bio; Speakers' Bureau(s) relationship with Tempus |
| Casey | Cosgrove | Consulting relationship with Intuitive Surgical Ltd; Consulting relationship with GSK; Consulting relationship with AZ; Consulting relationship with Immunogen; Consulting relationship with Merck; Consulting relationship with GSK; Research support relationship with Regeneron |
| Isabela | Covelli Velez | No Relevant Financial Relationships |
| Janelle | Darby | No Relevant Financial Relationships |
| Kathleen | Darcy | No Relevant Financial Relationships |
| Michael | Desjardins | No Relevant Financial Relationships |
| Nerlyne | Desravines | No Relevant Financial Relationships |
| Jhalak | Dholakia | No Relevant Financial Relationships |
| Kemi | Doll | No Relevant Financial Relationships |
| Lauren | Dori | No Relevant Financial Relationships |
| Sean | Dowdy | No Relevant Financial Relationships |
| Nefertiti | duPont | Board Membership relationship with Sanara Med Tech; Personal; Consulting relationship with GSK; Personal |
| Linda | Duska | Scientific advisory boards relationship with Aadi Bioscience; Scientific advisory boards relationship with Regeneron; Scientific advisory boards relationship with Merck; Service on the Editorial Board relationship with British Journal of Obstetrics and Gynaecology; Writing expert content relationship with UpToDate; Investigator-initiated trials relationship with Merck; Clinical trial grants (to institution) relationship with Genentech/Roche; Clinical trial grants (to institution) relationship with AbbVie/(GOG 3005); Clinical trial grants (to institution) relationship with Acrivon; Clinical trial grants (to institution) relationship with Advaxis; Clinical trial grants (to institution) relationship with Aduro BioTech; Clinical trial grants (to institution) relationship with Alkermes; Clinical trial grants (to institution) relationship with Blueprint; Clinical trial grants (to institution) relationship with Constellation; Clinical trial grants (to institution) relationship with Eisai; Clinical trial grants (to institution) relationship with GlaxoSmithKlein/Novartis; Clinical trial grants (to institution) relationship with Immunogen; Clinical trial grants (to institution) relationship with Inovio; Clinical trial grants (to institution) relationship with Iovance; Clinical trial grants (to institution) relationship with Karyopharm; Clinical trial grants (to institution) relationship with KSQ Therapeutics; Clinical trial grants (to institution) relationship with Lycera; Clinical trial grants (to institution) relationship with Merck; Clinical trial grants (to institution) relationship with Morab; Clinical trial grants (to institution) relationship with MorphoTek; Clinical trial grants (to institution) relationship with Naveris; Clinical trial grants (to institution) relationship with Nurix; Clinical trial grants (to institution) relationship with OncoQuest; Clinical trial grants (to institution) relationship with Pfizer; Clinical trial grants (to institution) relationship with Syndax; Clinical trial grants (to institution) relationship with Tesaro; Clinical trial grants (to institution) relationship with Zentalis; Safety monitoring committees relationship with Aegenus; Membership of data committees relationship with Aegenus; Safety monitoring committees relationship with Innovio; Membership of data committees relationship with Innovio |
| Mark | Einstein | Consulting relationship with Papivax; Rutgers (employer) receives compenstation; Rutgers (employer) receives compensation relationship with Merck; Rutgers (employer) receives compenstation; Rutgers (employer) receives compensation relationship with PDS Biotechnologies; Rutgers (employer) receives compenstation; Rutgers (employer) receives compensation relationship with Merck; Rutgers (employer) receives compenstation; Consulting relationship with Becton Dickenson; Consulting relationship with Douglas Pharma; Consulting relationship with Papivax; Consulting relationship with Merck; Consulting relationship with PDS; Consulting relationship with Douglas Pharma; Consulting relationship with Becton-Dickenson; Consulting relationship with Abbott Diagnostics |
| Kevin | Elias | No Relevant Financial Relationships |
| Britt | Erickson | Consulting relationship with GSK; Consulting relationship with Immunogen; Consulting relationship with AbbVie; Consulting relationship with AstraZeneca; Consulting relationship with AstraZeneca; Consulting relationship with GSK; Consulting relationship with Gilead; Consulting relationship with Merck |
| Ane Gerda | Eriksson | No Relevant Financial Relationships |
| Ramez | Eskander | Consulting relationship with RNE reports receiving institutional research support from AstraZeneca; Clovis Oncology; Eisai;; Grant relationship with RNE reports receiving institutional research support from Novocure; Consulting relationship with RNE reports receiving consulting and advisory fees from AstraZeneca; Cardiff Oncology;; Consulting relationship with RNE reports receiving consulting Eisai; Elevar Therapeutics; Genentech/Roche; GSK; ImmunoGen, Inc;; Consulting relationship with RNE reports receiving consulting and advisory fees from A Clovis Oncology Mersana; Myriad;; Consulting relationship with RNE reports receiving consulting and advisory fees from Daiichi Sankyo; Jiangsu Hengrui Pharmaceutic; Consulting relationship with AstraZeneca; Consulting relationship with GSK; Consulting relationship with Regeneron; Consulting relationship with Clovis Oncology; Consulting relationship with Repare Therapeutics; Consulting relationship with Eisai; Consulting relationship with MSD; Consulting relationship with Myriad; Consulting relationship with PMV Pharmaceuticals; Consulting relationship with Daiichi Sankyo; Consulting relationship with Novocure; Consulting relationship with AbbVie; Consulting relationship with Seagen |
| Amanda | Fader | Advisory Board relationship with Verastem; Advisory Board relationship with GSK |
| Lindsay | Ferguson | No Relevant Financial Relationships |
| James | Ferriss | No Relevant Financial Relationships |
| Katherine | Fuh | Consulting relationship with AstraZeneca; Consulting relationship with Abbvie; Consulting relationship with GSK |
| David | Gaffney | Chair DSMC relationship with Merck |
| Stephanie | Gaillard | Grant relationship with AstraZeneca; Consulting relationship with AstraZeneca; Grant relationship with Beigene; Grant relationship with Blueprint; Grant relationship with Compugen; Consulting relationship with Compugen; Grant relationship with Pharma&; Grant relationship with Immunogen; Grant relationship with Tempest; Consulting relationship with Verastem; Grant relationship with Volastra; Grant relationship with Verastem |
| Charlotte | Gamble | No Relevant Financial Relationships |
| Qinglei | Gao | No Relevant Financial Relationships |
| Paola | Gehrig | No Relevant Financial Relationships |
| Gretchen | Glaser | No Relevant Financial Relationships |
| Barbara | Goff | No Relevant Financial Relationships |
| Abby | Gonik | No Relevant Financial Relationships |
| Michael | Goodheart | No Relevant Financial Relationships |
| Tamar | Gootzen | No Relevant Financial Relationships |
| Ashley | Graul | No Relevant Financial Relationships |
| Maya | Gross | No Relevant Financial Relationships |
| Jennifer | Haag | No Relevant Financial Relationships |
| Andrea | Hagemann | No Relevant Financial Relationships |
| Tracilyn | Hall | No Relevant Financial Relationships |
| Gillian | Hanley | No Relevant Financial Relationships |
| Melissa | Hardesty | Consulting relationship with GSK; Consulting relationship with Imunogen; Consulting relationship with AstraZeneca; Consulting relationship with Eisai; Consulting relationship with Sankyo; Speakers' Bureau(s) relationship with Merck |
| Shariska | Harrington | No Relevant Financial Relationships |
| John | Hays | Consulting relationship with Pfizer; Personal; Consulting relationship with AstraZeneca; Personal; Consulting relationship with Deciphera; Personal; Grant relationship with Deciphera; Institutional; Grant relationship with Beigene; Institutional; Grant relationship with Eisai; Institutional; Grant relationship with EMD Serono; Institutional; Consulting relationship with Mersana; Personal; Consulting relationship with Mural Oncology |
| Vanessa | Hill | No Relevant Financial Relationships |
| R. Tyler | Hillman | Grant relationship with Sumitomo Pharma |
| Sharonne | Holtzman | No Relevant Financial Relationships |
| Jeffrey | How | No Relevant Financial Relationships |
| Warner | Huh | No Relevant Financial Relationships |
| Megan | Hutchcraft | No Relevant Financial Relationships |
| In Sun | Hwang | No Relevant Financial Relationships |
| Yevgeniya | Ioffe | Consulting relationship with GlaxoSmithKline |
| Sara | Isani | No Relevant Financial Relationships |
| Sophie | Jabban | No Relevant Financial Relationships |
| Amanda | Jackson | Consulting relationship with Ethicon; Speakers' Bureau(s) relationship with OncLive; Advisory Board relationship with AstraZeneca |
| Jo Marie | Janco | No Relevant Financial Relationships |
| Amelia | Jernigan | Speakers' Bureau(s) relationship with AstraZeneca; Consulting relationship with Merch |
| Fang | Jiang | No Relevant Financial Relationships |
| Evonne | Kandas | No Relevant Financial Relationships |
| Anthony | Karnezis | No Relevant Financial Relationships |
| Kenneth | Kim | No Relevant Financial Relationships |
| Rachel Soyoun | Kim | No Relevant Financial Relationships |
| Sang Wun | Kim | No Relevant Financial Relationships |
| Sarah | Kim | No Relevant Financial Relationships |
| Emily | Ko | Grant relationship with Tesaro; Grant relationship with Faeth; Grant relationship with Bristow-Myers Squibb; Grant relationship with GSK |
| Gottfried | Konecny | Speakers' Bureau(s) relationship with AstraZeneca; Speakers' Bureau(s) relationship with Immunogen; Grant relationship with Lilly; Grant relationship with Merck; Travel relationship with TORL Biotherapeutics |
| Panagiotis | Konstantinopoulos | Board Membership relationship with AstraZeneca; Consulting relationship with Foundation Medicine; Consulting relationship with Immunogen; Consulting relationship with Novartis; Consulting relationship with GSK; Consulting relationship with BMS; Consulting relationship with Artios; Consulting relationship with Merck KGaA; Consulting relationship with Scorpion; Consulting relationship with Mural Oncology; Consulting relationship with Nimbus |
| Amanika | Kumar | No Relevant Financial Relationships |
| Lindsay | Kuroki | No Relevant Financial Relationships |
| David | Kushner | No Relevant Financial Relationships |
| Geeta | Lal | No Relevant Financial Relationships |
| Clarissa | Lam | No Relevant Financial Relationships |
| Chunyan | Lan | No Relevant Financial Relationships |
| Charles | Landen | No Relevant Financial Relationships |
| Megan | Lander | No Relevant Financial Relationships |
| Lisa | Landrum | Consulting relationship with Glaxo Smith Kline |
| Olivia | Lara | No Relevant Financial Relationships |
| Jung-Yun | Lee | Grant relationship with AstraZeneca; Grant relationship with Beigene; Grant relationship with Eisai; Grant relationship with GSK; Grant relationship with MSD; Grant relationship with Regeneron; Grant relationship with Seagen; Grant relationship with Sutro |
| Sarah | Lee | No Relevant Financial Relationships |
| Yeon Woo | Lee | No Relevant Financial Relationships |
| Carolyn | Lefkowits | Advisory Board relationship with Vertext Pharmaceuticals |
| Mario | Leitao | Consulting relationship with Medtronic; Speakers' Bureau(s) relationship with Intuitive Surgical; Board Membership relationship with JnJ/Ethicon; Board Membership relationship with Immunogen |
| Ernst | Lengyel | Grant relationship with Abbvie; Grant relationship with Arsenal Bioscience |
| Kimberly | Levinson | No Relevant Financial Relationships |
| Ken | Lin | Stockholder/Shareholder relationship with Novo Nordisk |
| Lilie | Lin | Advisory Board Participation relationship with AstraZeneca; Advisory Board Participation relationship with Daiichi Sankyo; Advisory Board Participation relationship with Eisai; Advisory Board Participation relationship with GlaxoSmithKline; Advisory Board Participation relationship with Zentalis; Consulting relationship with Bristol-Myers Squibb; Institutional PI of Trial relationship with Aravive; Institutional PI of Trial relationship with AstraZeneca; PI of Trial/IST relationship with Bristol-Myers Squibb; PI of Trial/IST relationship with AstraZeneca; Institutional PI of Trial relationship with Clovis Oncology; Institutional PI for Trial relationship with GlaxoSmithKline; Institutional PI of Trial relationship with Impact Therapeutics; Institutional PI of Trial relationship with Regeneron; Advisory Board Participation relationship with Genentech; Institutional PI of Trial relationship with SystImmune; Institutional PI of Trial relationship with Volastra; Institutional PI of Trial relationship with Seagen/Pfizer |
| Melissa | Lippitt | No Relevant Financial Relationships |
| Ramey | Littell | No Relevant Financial Relationships |
| Joyce | Liu | Advisory Board Participation relationship with AstraZeneca; Advisory Board Participation relationship with Daiichi Sankyo; Advisory Board Participation relationship with Eisai; Advisory Board Participation relationship with GlaxoSmithKline; Advisory Board Participation relationship with Zentalis; Consulting relationship with Bristol-Myers Squibb; Institutional PI of Trial relationship with Aravive; Institutional PI of Trial relationship with AstraZeneca; PI of Trial/IST relationship with Bristol-Myers Squibb; PI of Trial/IST relationship with AstraZeneca; Institutional PI of Trial relationship with Clovis Oncology; Institutional PI for Trial relationship with GlaxoSmithKline; Institutional PI of Trial relationship with Impact Therapeutics; Institutional PI of Trial relationship with Regeneron; Advisory Board Participation relationship with Genentech; Institutional PI of Trial relationship with SystImmune; Institutional PI of Trial relationship with Volastra; Institutional PI of Trial relationship with Seagen/Pfizer |
| Kara | Long Roche | No Relevant Financial Relationships |
| Domenica | Lorusso | Board Membership relationship with Astrazeneca; Speakers' Bureau(s) relationship with Astrazeneca; Consulting relationship with Astrazeneca; Grant relationship with Astrazeneca; Consulting relationship with Astrazeneca; Board Membership relationship with Clovis Oncology; Speakers' Bureau(s) relationship with Clovis Oncology; Grant relationship with Clovis Oncology; Board Membership relationship with Corcept; Grant relationship with Corcept; Speakers' Bureau(s) relationship with Daiichi Sankyo; Board Membership relationship with Genmab; Speakers' Bureau(s) relationship with Genmab; Speakers' Bureau(s) relationship with Astrazeneca; Grant relationship with Genmab; Board Membership relationship with GSK; Speakers' Bureau(s) relationship with GSK; Grant relationship with GSK; Speakers' Bureau(s) relationship with GSK; Speakers' Bureau(s) relationship with Immunogen; Board Membership relationship with Immunogen; Grant relationship with Immunogen; Board Membership relationship with MSD; Speakers' Bureau(s) relationship with MSD; Grant relationship with MSD; Speakers' Bureau(s) relationship with MSD; Consulting relationship with MSD; Consulting relationship with NOVARTIS; Grant relationship with NOVARTIS; Board Membership relationship with ONCOINVEST; Board Membership relationship with Novocure; Board Membership relationship with Seagen; Grant relationship with Seagen; Board Membership relationship with sutro; Grant relationship with Pharma&; Grant relationship with Incyte; Grant relationship with Pharmamar; Grant relationship with Roche; Grant relationship with Alkermes; Speakers' Bureau(s) relationship with Menarini; Board Membership relationship with GCIG; Board Membership relationship with MITO; Board Membership relationship with ENGOT |
| Karen | Lu | No Relevant Financial Relationships |
| Helen | MacKay | Consulting relationship with Glaxo Smith Kline; Consulting relationship with Merck; Consulting relationship with Essai; Consulting relationship with Astra Zeneca |
| Katherine | Mahar | No Relevant Financial Relationships |
| Adrianne | Mallen | No Relevant Financial Relationships |
| William | Manning | No Relevant Financial Relationships |
| Benjamin | Matthews | No Relevant Financial Relationships |
| Jyoti | Mayadev | Consulting relationship with Merck; Consulting relationship with Astra Zeneca; Consulting relationship with Primmune; Board Membership relationship with American Brachytherapy Society; Board Membership relationship with GOG Foundation; Consulting relationship with Varian Medical Systems; Board Membership relationship with Primmune; Consulting relationship with NRG Oncology; Consulting relationship with Kortuc; Consulting relationship with AstraZeneca; Consulting relationship with Merck |
| Jessica | McAlpine | Speakers' Bureau(s) relationship with GSK; Speakers' Bureau(s) relationship with Astra Zeneca |
| Leah | McNally | No Relevant Financial Relationships |
| Alexander | Melamed | Consulting relationship with Axena Healthcare Inc |
| Alberto | Mendivil | No Relevant Financial Relationships |
| Larissa | Meyer | research funding relationship with Astra Zeneca; ongoing; Research grant relationship with Merck; Stockholder/Shareholder - publicly traded relationship with Walgreens; Stockholder/Shareholder - publicly traded relationship with Johnson and Johnson; Stockholder/Shareholder - publicly traded relationship with Crispr; Stockholder/Shareholder - publicly traded relationship with Denali; Stockholder/Shareholder - publicly traded relationship with Bristol Myers Squibb |
| Linda | Miller | No Relevant Financial Relationships |
| Kathryn | Mills | Consulting relationship with Stryker, Inc. |
| Susan | Modesitt | Grant relationship with Ergomed; Clinical trial support relationship with Mersana; Speakers' Bureau(s) relationship with Eisai; Clinical trial support relationship with Corcept |
| Shilpa | Mokshagundam | No Relevant Financial Relationships |
| Kathleen | Moore | advisory boards relationship with astra zeneca, aadi, aravive, alkemeres, blueprint, caris,; Consulting relationship with duality, daiichi sankyo, eisai, gsk, genentech/roche,; Consulting relationship with immunogen, imab, janssen, lilly, mereo, merck, mersana,; Consulting relationship with myriad, novarits, oncxerna, onconova, pannavance, regeneron; Consulting relationship with verastem, vbl therapeutics, zentalis |
| Adriana | Moura | Speakers' Bureau(s) relationship with Astrazeneca; Speakers' Bureau(s) relationship with MSD; Speakers' Bureau(s) relationship with GSK |
| Vaidehi | Mujumdar | No Relevant Financial Relationships |
| Fernanda | Musa | Consulting relationship with GSK; Speakers' Bureau(s) relationship with Merck; Consulting relationship with Astra Zeneca; Grant relationship with Allarity; Consulting relationship with Duality Bio; Grant relationship with Constellation; Consulting relationship with Aadi; Consulting relationship with Daiichi Sankyo; Consulting relationship with BioNTech; Consulting relationship with Genmab |
| Christa | Nagel | No Relevant Financial Relationships |
| Dimitrios | Nasioudis | No Relevant Financial Relationships |
| Jude | Nawlo | No Relevant Financial Relationships |
| Gregg | Nelson | Grant relationship with Pfizer; Speakers' Bureau(s) relationship with Intuitive; Advisory Board relationship with Integra Life Sciences; Advisory Board relationship with Smith & Nephew |
| Nicole | Nevadunsky | No Relevant Financial Relationships |
| Angela | Nolin | No Relevant Financial Relationships |
| Roisin | O'Cearbhaill | Institutional Support for Clinical Trial relationship with Arsenal-Bio; Institutional Support for Clinical Trial relationship with Atara Biotherapeutics; Institutional Support for Clinical Trial relationship with Genentech; Institutional Support for Clinical Trial relationship with Genmab/Seagen; Advisory board relationship with Seagen; Advisory board relationship with 2seventybio; Advisory board relationship with GSK; Advisory board relationship with Immunogen; Institutional Support for Clinical Trial relationship with Kite Pharma; Institutional Support for Clinical Trial relationship with Ludwig Cancer Institute; Institutional Support for Clinical Trial relationship with Lyell Therapeutics; Institutional Support for Clinical Trial relationship with Marker Therapeutics; Institutional Support for Clinical Trial relationship with Merck; Advisory board relationship with Miltenyi; Institutional Support for Clinical Trial relationship with Regeneron; Institutional Support for Clinical Trial relationship with Sellas Therapeutics; Institutional Support for Clinical Trial relationship with Syndax Pharmaceuticals; Institutional Support for Clinical Trial relationship with TCR2 Therapeutics; Institutional Support for Clinical Trial relationship with Tesaro/GSK; Institutional Support for Clinical Trial relationship with Alkermes |
| Alexander | Olawaiye | Scientific Advisory Board relationship with AstraZeneca; Personal; Scientific Advisory Board relationship with GSK; Personal; Scientific Advisory Board relationship with Clovis; Personal; Scientific Advisory Board relationship with Genentech; Personal; Grant relationship with Corcept |
| Ann | Oluloro | Grant relationship with Merck |
| Yukihide | Ota | No Relevant Financial Relationships |
| Elena | Pereira | No Relevant Financial Relationships |
| Jonathan | Perlin | No Relevant Financial Relationships |
| jurgen | Piek | No Relevant Financial Relationships |
| Vinita | Popat | No Relevant Financial Relationships |
| Bhavana | Pothuri | Grant relationship with Agenus; Grant relationship with AstraZeneca; Grant relationship with Celgene; Grant relationship with Celsion/Immunon; Grant relationship with Clovis Oncology; Grant relationship with Eisai; Grant relationship with Imab; Grant relationship with Immunogen; Grant relationship with Incyte; Grant relationship with Karyopharm; Grant relationship with Merck; Grant relationship with Mersana; Grant relationship with Onconova; Grant relationship with Roche/Genentech; Grant relationship with Seagen; Grant relationship with Takeda; Grant relationship with Tesaro/GSK; Grant relationship with Xencor; Consulting relationship with AstraZeneca; Consulting relationship with Eisai; Consulting relationship with Immunogen; Consulting relationship with Incyte Corporation; Consulting relationship with Merck; Consulting relationship with Lilly; Consulting relationship with Onconova Therapeutics; Consulting relationship with R Pharm; Consulting relationship with Tesaro/GSK; Advisory Board relationship with AstraZeneca; Advisory Board relationship with Imab; Advisory Board relationship with Merck; Advisory Board relationship with Mersana; Advisory Board relationship with Onconova; Advisory Board relationship with Tesaro/GSK; Consulting relationship with GSK; Personal; Grant relationship with GSK; Institutional; Grant relationship with merck; Institutional; Grant relationship with Astra Zeneca; Institutional; Consulting relationship with Imvax; Consulting relationship with Regeneron; Consulting relationship with Signatera |
| Matthew | Powell | Consulting relationship with AstraZeneca Pharma; Research support relationship with GlaxoSmithKline; Consulting relationship with Merck Sharp & Dohme; Consulting relationship with Aadi Bioscience |
| Allison | Puechl | No Relevant Financial Relationships |
| Leslie | Randall | Speakers' Bureau(s) relationship with Seagen/Pfizer; Speakers' Bureau(s) relationship with Genmab; Consulting relationship with GSK; Consulting relationship with Merck; Consulting relationship with Immunogen/Abbvie; Consulting relationship with AstraZeneca; Consulting relationship with Genentech/Roche; yes; Consulting relationship with GSK/Tesaro; Consulting relationship with Merck; Grant relationship with Merck; Consulting relationship with SeaGen; Consulting relationship with Immunogen |
| Isabelle | Ray Coquard | Consulting relationship with GSK; Consulting relationship with astra zeneca; Consulting relationship with immunogen; Consulting relationship with DAIICHI |
| Debra | Richardson | Consulting relationship with Mersana; Consulting relationship with AstraZeneca; Consulting relationship with GlaxoSmithKline; Consulting relationship with ProfoundBio; Consulting relationship with Eisai; Consulting relationship with Immunogen; Consulting relationship with Daiichi Sankyo; Grant relationship with GlaxoSmithKline; research support relationship with Mersana; clinical trial relationship with AstraZeneca; clinical trial relationship with Profound Bio; clinical trial relationship with Immunogen; clinical trial relationship with Karyopharm; clinical trial relationship with Lilly; clinical trial relationship with Celsion; clinical trial relationship with Hookipa; clinical trial relationship with CanarioBio; clinical trial relationship with Acrivon; clinical trial relationship with PMV pharmaceuticals; clinical trial relationship with Nurix Therapeutics; clinical trial relationship with Nimbus Therapeutics; clinical trial relationship with DualityBio; clinical trial relationship with Blueprint Medicines; clinical trial relationship with Allorian; clinical trial relationship with A2A pharmaceuticals; clinical trial relationship with OnCusp Therapeutics; clinical trial relationship with Valerio Therapeutics; clinical trial relationship with Aadi; clinical trial relationship with Shattuck Labs |
| B.J. | Rimel | Consulting relationship with GSk; Consulting relationship with AstraZeneca; Consulting relationship with Merck; Consulting relationship with GSK; Advisory board participant relationship with Merck; Advisory board participant relationship with Immunogen; Advisory board participant relationship with AstraZeneca |
| Eric | Rios-Doria | No Relevant Financial Relationships |
| Lorna | Rodriguez-Rodriguez | No Relevant Financial Relationships |
| Emma | Rossi | patient safety advisor relationship with Medtronic |
| Emma | Rossi | patient safety advisor relationship with Medtronic |
| Bunja | Rungruang | No Relevant Financial Relationships |
| Tracy | Sandstrom | No Relevant Financial Relationships |
| Kevin | Schuler | No Relevant Financial Relationships |
| Gretchen | Schwarze | Consulting relationship with Vital Talk |
| Kala | Seawright | No Relevant Financial Relationships |
| Mark | Shahin | No Relevant Financial Relationships |
| David | Shalowitz | Advisory Board relationship with Verastem Oncology; Yes |
| Sameer | Sharma | No Relevant Financial Relationships |
| Tiffany | Sia | No Relevant Financial Relationships |
| Travis | Sims | Grant relationship with Bristol Myers Squibb; Grant relationship with Gilead Sciences; Grant relationship with National Institute of Health (NIH); Consulting relationship with AstraZeneca |
| Abdulrahman | Sinno | No Relevant Financial Relationships |
| Rachel | Sisodia | No Relevant Financial Relationships |
| Brian | Slomovitz | Consulting relationship with Abbvie; Personal; Consulting relationship with AstraZeneca; Personal; Consulting relationship with Clovis; Personal; Consulting relationship with Merck; Personal; Consulting relationship with Myriad; Personal; Consulting relationship with GOG Foundation; Personal; Consulting relationship with GSK; Personal; Consulting relationship with Genentech; Personal; Consulting relationship with Lilly; Personal; Consulting relationship with Imvax; Personal; Consulting relationship with Karyopharm; Personal; Consulting relationship with Eisai; Personal; Consulting relationship with Incyte; Personal; Consulting relationship with Seagen; Personal; Consulting relationship with Genmab; Personal; Consulting relationship with Novartis; Personal |
| Anna Jo | Smith | Grant relationship with GSK; Honoraria relationship with Total Health Conferencing |
| Mihae | Song | No Relevant Financial Relationships |
| Ryan | Spencer | No Relevant Financial Relationships |
| Lori | Spoozak | No Relevant Financial Relationships |
| Jessica | St Laurent | No Relevant Financial Relationships |
| Kristen | Starbuck | No Relevant Financial Relationships |
| Miranda | Steenbeek | No Relevant Financial Relationships |
| Taylor | Stewart | No Relevant Financial Relationships |
| Rebecca | Stone | Grant relationship with Pacira Pharmaceuticals; Consulting relationship with AstraZeneca |
| Dong Hoon | Suh | No Relevant Financial Relationships |
| Elizabeth | Swisher | Board Membership relationship with ideaya bioscience; clinical trial funding to institution relationship with GlaxoSmithKline; clinical trial funding to institution relationship with Plexxicon |
| jie | tang | No Relevant Financial Relationships |
| Kristin | Taylor | Consulting relationship with Abbvie |
| Sarah | Taylor | No Relevant Financial Relationships |
| Deanna | Teoh | Research support relationship with GSK; Research support relationship with Moderna; Research support relationship with Jounce Therapeutics; Single ad board participation relationship with Asieris |
| Laura | Testuser | No Relevant Financial Relationships |
| Scott | Testuser | No Relevant Financial Relationships |
| Surabhi | Tewari | No Relevant Financial Relationships |
| Premal | Thaker | Consulting relationship with Astra Zeneca; Consulting relationship with Glaxo Smith Kline; Grant relationship with Glaxo Smith Kline; Consulting relationship with Merck; Grant relationship with Merck; Board Membership relationship with Iovance; Consulting relationship with Pfizer; Consulting relationship with Corcept Therapeutics; Consulting relationship with Zentalis; Consulting relationship with Verastem; Consulting relationship with Imunon; Stockholder/Shareholder - privately held relationship with Imunon; Consulting relationship with Caris |
| Michael | Toboni | No Relevant Financial Relationships |
| Katherine | Tucker | No Relevant Financial Relationships |
| Shitanshu | Uppal | No Relevant Financial Relationships |
| Renata | Urban | No Relevant Financial Relationships |
| Toon | Van Gorp | Consulting relationship with AstraZeneca; Consulting relationship with Eisai; Consulting relationship with GSK; Consulting relationship with ImmunoGen; Consulting relationship with MSD/Merck; Consulting relationship with OncXerna Therapeutics; Consulting relationship with Seagen; Consulting relationship with Tubulis; Grant relationship with AstraZeneca; Grant relationship with Roche; Grant relationship with Amgen; Speakers' Bureau(s) relationship with AstraZeneca; Speakers' Bureau(s) relationship with GSK; Speakers' Bureau(s) relationship with ImmunoGen; Travel, accommodations, expenses relationship with AstraZeneca; Travel, accommodations, expenses relationship with GSK; Travel, accommodations, expenses relationship with ImmunoGen; Travel, accommodations, expenses relationship with MSD; Travel, accommodations, expenses relationship with PharmaMar |
| Roberto | Vargas | No Relevant Financial Relationships |
| Matt | Wagar | No Relevant Financial Relationships |
| Mark | Wakabayashi | Employee/Founding Member relationship with Regneron Pharmaceuticals; Personal |
| Christopher | Walker | No Relevant Financial Relationships |
| Christine | Walsh | Consulting relationship with Regeneron |
| Meryl | Warshafsky | No Relevant Financial Relationships |
| Christina | Washington | No Relevant Financial Relationships |
| Lari | Wenzel | No Relevant Financial Relationships |
| Shannon | Westin | Consulting relationship with AstraZeneca; Grant relationship with AstraZeneca; Grant relationship with AvengeBio; Grant relationship with Bayer; Grant relationship with Bio-Path; Consulting relationship with Caris; Consulting relationship with Clovis Oncology; Grant relationship with Clovis Oncology; Consulting relationship with GSK; Grant relationship with GSK; Consulting relationship with Eisai; Consulting relationship with EQRX; Consulting relationship with Gilead; Consulting relationship with Immunocore; Consulting relationship with Immunogen; Grant relationship with Jazz Pharmaceuticals; Consulting relationship with Lilly; Consulting relationship with Merck; Consulting relationship with Mereo; Grant relationship with Mereo; Consulting relationship with Mersana; Grant relationship with Novartis; Consulting relationship with NGM Bio; Consulting relationship with Nuvectis; Grant relationship with Nuvectis; Consulting relationship with Roche/Genentech; Grant relationship with Roche/Genentech; Consulting relationship with SeaGen; Consulting relationship with Verastem; Consulting relationship with Vincerx; Consulting relationship with Zentalis; Grant relationship with Zentalis; Consulting relationship with ZielBio; Consulting relationship with Corcept; Consulting relationship with Daiichi Sankyo; Consulting relationship with Loxo |
| Stephanie | Wethington | Employee/Founding Member relationship with FDA (Corrrected) |
| Liz | Wiseman | No Relevant Financial Relationships |
| Jason | Wright | Grant relationship with Merck; Honoraria relationship with UpToDate; Honoraria relationship with American College of Obstetricians and Gynecologists; Grant relationship with Merck; Institutional; Royalties relationship with UpToDate; Personal; Honoraria relationship with ACOG; Personal |
| Oladapo | Yeku | Consulting relationship with GIMV NV; Consulting relationship with TigaTx Inc; Board Membership relationship with hC Bioscience |
| Ting-Tai | Yen | No Relevant Financial Relationships |
| Benoit | You | No Relevant Financial Relationships |
| Jennifer | Young Pierce | No Relevant Financial Relationships |
| Abigail | Zamorano | No Relevant Financial Relationships |
| Nancy | Zhou | No Relevant Financial Relationships |
| Emese | Zsiros | Board Membership relationship with Merck; Consulting relationship with Iovance; Consulting relationship with Nextcure; Consulting relationship with Nurix |